RCUS · Arcus Biosciences, Inc. · Documents
$23.75
+1.61 (+7.27%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$2.82B
Shares
127.33M
Volume · Oct 20
6.24M
Avg daily vol (3M)
1.49M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| Investor Event Transcript | ARCUS said anemia from castatophant is monitored and treated with ESAs or transfusions without reported discontinuations; hypoxia may lead patients to take a holiday or lower the dose, but patients generally remain on therapy. | 2026-10-20 | 2026-12-31 | |
| 8-K | Arcus Biosciences presented new ARC-20 data for casdatifan in clear cell renal cell carcinoma: first-line combination PFS was 86% at six months and 69% at 12 months; second-line combination median PFS was 14.5 months; late-line monotherapy median overall survival was 35 months. | 2026-10-20 | — | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-09 | 2026-09-30 | |
| 8-K | — | 2026-08-05 | — | |
| 10-Q | — | 2026-08-05 | 2026-06-30 | |
| 8-K | — | 2026-06-12 | 2026-06-11 | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| 10-Q | — | 2026-05-05 | 2026-03-31 | |
| 8-K | — | 2026-05-05 | — | |
| ARS | — | 2026-04-21 | 2025-12-31 | |
| DEF 14A | — | 2026-04-21 | 2026-06-11 | |
| DEFA14A | — | 2026-04-21 | — | |
| 8-K | — | 2026-04-20 | — | |
| 8-K | — | 2026-03-23 | 2026-03-17 | |
| Investor Event Transcript | — | 2026-03-09 | 2026-03-31 | |
| S-3ASR | — | 2026-02-25 | — | |
| 8-K | — | 2026-02-25 | — | |
| 10-K | — | 2026-02-25 | 2025-12-31 | |
| 8-K | — | 2025-12-18 | — | |
| 8-K | — | 2025-12-12 | — | |
| 8-K | — | 2025-11-03 | 2025-10-30 | |
| 8-K | — | 2025-10-28 | — | |
| 10-Q | — | 2025-10-28 | 2025-09-30 | |
| 8-K | — | 2025-10-14 | 2025-10-12 | |
| 8-K | — | 2025-10-06 | — | |
| 10-Q | — | 2025-08-06 | 2025-06-30 | |
| 8-K | — | 2025-08-06 | — | |
| 8-K | — | 2025-06-12 | 2025-06-10 | |
| 8-K | — | 2025-06-02 | 2025-06-01 | |
| 10-Q | — | 2025-05-06 | 2025-03-31 | |
| 8-K | — | 2025-05-06 | — | |
| DEF 14A | — | 2025-04-22 | 2025-06-10 | |
| ARS | — | 2025-04-22 | 2024-12-31 | |
| DEFA14A | — | 2025-04-22 | — | |
| 10-K | — | 2025-02-25 | 2024-12-31 | |
| 8-K | — | 2025-02-25 | — | |
| 8-K | — | 2025-02-19 | 2025-02-18 | |
| 8-K | — | 2025-02-18 | 2025-02-15 | |
| 8-K | — | 2025-02-06 | — | |
| 8-K | — | 2025-01-21 | 2025-01-16 | |
| 10-Q | — | 2024-11-06 | 2024-09-30 | |
| 8-K | — | 2024-11-06 | — | |
| 8-K | — | 2024-10-24 | — | |
| 8-K | — | 2024-08-27 | — | |
| 8-K | — | 2024-08-08 | — | |
| 10-Q | — | 2024-08-08 | 2024-06-30 | |
| 8-K | — | 2024-06-06 | — | |
| 8-K | — | 2024-06-03 | 2024-06-02 | |
| 8-K | — | 2024-05-23 | — |
Showing 1–50 of 132 filings
Key facts
CIK
1724521
CUSIP
03969F109
13F (30d)
19 filings
19 filers
Visit website
Investor relations